

Daniel C Brennan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4702619/publications.pdf>

Version: 2024-02-01

262
papers

16,886
citations

20759

60
h-index

17055

122
g-index

266
all docs

266
docs citations

266
times ranked

12693
citing authors

#	ARTICLE	IF	CITATIONS
1	International Trial of the Edmonton Protocol for Islet Transplantation. <i>New England Journal of Medicine</i> , 2006, 355, 1318-1330.	13.9	1,754
2	Polyomavirus-Associated Nephropathy in Renal Transplantation: Interdisciplinary Analyses and Recommendations. <i>Transplantation</i> , 2005, 79, 1277-1286.	0.5	842
3	Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplantation. <i>New England Journal of Medicine</i> , 2006, 355, 1967-1977.	13.9	675
4	Incidence of BK with Tacrolimus Versus Cyclosporine and Impact of Preemptive Immunosuppression Reduction. <i>American Journal of Transplantation</i> , 2005, 5, 582-594.	2.6	613
5	Identification of a Novel Polyomavirus from Patients with Acute Respiratory Tract Infections. <i>PLoS Pathogens</i> , 2007, 3, e64.	2.1	581
6	Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial. <i>Transplantation</i> , 2009, 87, 233-242.	0.5	524
7	Cell-Free DNA and Active Rejection in Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2221-2232.	3.0	365
8	Incidence and Cost of New Onset Diabetes Mellitus Among U.S. Wait-Listed and Transplanted Renal Allograft Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 590-598.	2.6	354
9	A RANDOMIZED, DOUBLE-BLINDED COMPARISON OF THYMOGLOBULIN VERSUS ATGAM FOR INDUCTION IMMUNOSUPPRESSIVE THERAPY IN ADULT RENAL TRANSPLANT RECIPIENTS ^{1,2} . <i>Transplantation</i> , 1999, 67, 1011-1018.	0.5	341
10	Incidence and Predictors of Myocardial Infarction after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 496-506.	3.0	307
11	Prophylactic Versus Preemptive Oral Valganciclovir for the Management of Cytomegalovirus Infection in Adult Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2006, 6, 2134-2143.	2.6	294
12	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION ^{1,2} . <i>Transplantation</i> , 1998, 66, 29-37.	0.5	273
13	Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus Management in Solid Organ Transplantation Final Report. <i>American Journal of Transplantation</i> , 2005, 5, 218-227.	2.6	268
14	The Effect of Tolerance to Noninherited Maternal HLA Antigens on the Survival of Renal Transplants from Sibling Donors. <i>New England Journal of Medicine</i> , 1998, 339, 1657-1664.	13.9	267
15	Racial Variation in Medical Outcomes among Living Kidney Donors. <i>New England Journal of Medicine</i> , 2010, 363, 724-732.	13.9	261
16	Donor Origin of BK Virus in Renal Transplantation and Role of HLA C7 in Susceptibility to Sustained BK Viremia. <i>American Journal of Transplantation</i> , 2005, 5, 2213-2221.	2.6	251
17	RECURRENT AND DE NOVO GLOMERULAR DISEASE AFTER RENAL TRANSPLANTATION. <i>Transplantation</i> , 1999, 68, 635-641.	0.5	213
18	Cytomegalovirus in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 848-855.	3.0	209

#	ARTICLE	IF	CITATIONS
19	Nomogram for Predicting the Likelihood of Delayed Graft Function in Adult Cadaveric Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2967-2974.	3.0	199
20	Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3114-3122.	3.0	172
21	Stimulated kidney tubular epithelial cells express membrane associated and secreted TNF α . <i>Kidney International</i> , 1991, 40, 203-211.	2.6	141
22	PROPHYLACTIC ORAL GANCICLOVIR COMPARED WITH DEFERRED THERAPY FOR CONTROL OF CYTOMEGALOVIRUS IN RENAL TRANSPLANT RECIPIENTS ^{1,2,???} . <i>Transplantation</i> , 1997, 64, 1843-1846.	0.5	141
23	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	0.8	139
24	Bariatric Surgery Among Kidney Transplant Candidates and Recipients: Analysis of the United States Renal Data System and Literature Review. <i>Transplantation</i> , 2009, 87, 1167-1173.	0.5	139
25	Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States. <i>American Journal of Transplantation</i> , 2016, 16, 509-517.	2.6	134
26	Review of Cytomegalovirus Infection Findings With Mammalian Target of Rapamycin Inhibitor-Based Immunosuppressive Therapy in De Novo Renal Transplant Recipients. <i>Transplantation</i> , 2012, 93, 1075-1085.	0.5	129
27	Obesity and Kidney Transplant Candidates: How Big Is Too Big for Transplantation?. <i>American Journal of Nephrology</i> , 2012, 36, 575-586.	1.4	124
28	Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1027-1034.	0.5	122
29	Five-Year Follow Up of Thymoglobulin Versus ATGAM Induction in Adult Renal Transplantation. <i>Transplantation</i> , 2004, 78, 136-141.	0.5	118
30	The Life-Years Saved by a Deceased Organ Donor. <i>American Journal of Transplantation</i> , 2005, 5, 2289-2296.	2.6	118
31	Human polyoma viruses and disease with emphasis on clinical BK and JC. <i>Journal of Clinical Virology</i> , 2010, 47, 306-312.	1.6	118
32	Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells. <i>Kidney International</i> , 1990, 38, 417-425.	2.6	114
33	SHORT COURSE INDUCTION IMMUNOSUPPRESSION WITH THYMOGLOBULIN FOR RENAL TRANSPLANT RECIPIENTS ¹ . <i>Transplantation</i> , 2002, 73, 473-475.	0.5	113
34	Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction. <i>New England Journal of Medicine</i> , 2008, 359, 1736-1738.	13.9	112
35	De Novo Congestive Heart Failure After Kidney Transplantation: A Common Condition With Poor Prognostic Implications. <i>American Journal of Kidney Diseases</i> , 2005, 46, 720-733.	2.1	110
36	The expanded criterial donor dilemma in cadaveric renal transplantation. <i>Transplantation</i> , 2003, 75, 1940-1945.	0.5	107

#	ARTICLE	IF	CITATIONS
37	Quantitative Polymerase Chain Reaction to Predict Occurrence of Symptomatic Cytomegalovirus Infection and Assess Response to Ganciclovir Therapy in Renal Transplant Recipients. <i>Journal of Infectious Diseases</i> , 1998, 178, 626-635.	1.9	101
38	BK virus antibody titers and intensity of infections after renal transplantation. <i>Journal of Clinical Virology</i> , 2008, 43, 184-189.	1.6	93
39	Cost-Effectiveness of Extending Medicare Coverage of Immunosuppressive Medications to the Life of a Kidney Transplant. <i>American Journal of Transplantation</i> , 2004, 4, 1703-1708.	2.6	90
40	Frailty and Access to Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 576-582.	2.2	89
41	Mesangial cell accessory functions: Mediation by intercellular adhesion molecule-1. <i>Kidney International</i> , 1990, 38, 1039-1046.	2.6	86
42	Switching <sc>ST</sc>udy of Kidney TRansplant <sc>PA</sc>tients with Tremor to <sc>LCP</sc>â€†acrO (<sc>STRATO</sc>): an openâ€label, multicenter, prospective phase 3b study. <i>Clinical Transplantation</i> , 2015, 29, 796-805.	0.8	86
43	Incidence, Risk Factors, and Sequelae of Post-kidney Transplant Delirium. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1752-1759.	3.0	86
44	Long-term kidney transplant graft survivalâ€”Making progress when most needed. <i>American Journal of Transplantation</i> , 2021, 21, 2824-2832.	2.6	86
45	Living donation decision making: recipients' concerns and educational needs. <i>Progress in Transplantation</i> , 2006, 16, 17-23.	0.4	86
46	Neutralization Serotyping of BK Polyomavirus Infection in Kidney Transplant Recipients. <i>PLoS Pathogens</i> , 2012, 8, e1002650.	2.1	83
47	The role of tacrolimus in renal transplantation. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 635-643.	0.9	82
48	PERIPHERAL BLOOD MICROCHIMERISM IN HUMAN LIVER AND RENAL TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1997, 64, 427-432.	0.5	81
49	Early Clinical Complications After ABO-Incompatible Live-Donor Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 54-65.	0.5	77
50	Colony stimulating factor-1 in the induction of lupus nephritis. <i>Kidney International</i> , 1993, 43, 1000-1009.	2.6	75
51	ECONOMIC COST OF EXPANDED CRITERIA DONORS IN CADAVERIC RENAL TRANSPLANTATION: ANALYSIS OF MEDICARE PAYMENTS ¹ . <i>Transplantation</i> , 2000, 70, 755-760.	0.5	75
52	Variations in the Risk for Cerebrovascular Events after Kidney Transplant Compared with Experience on the Waiting List and after Graft Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1090-1101.	2.2	75
53	Selection of induction therapy in kidney transplantation. <i>Transplant International</i> , 2013, 26, 662-672.	0.8	72
54	A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10-Year Results. <i>Transplantation</i> , 2008, 86, 947-952.	0.5	71

#	ARTICLE	IF	CITATIONS
55	CADAVERIC VERSUS LIVING DONOR KIDNEY TRANSPLANTATION. <i>Transplantation</i> , 2000, 69, 311.	0.5	71
56	DONOR-SPECIFIC TRANSFUSIONS HAVE LONG-TERM BENEFICIAL EFFECTS FOR HUMAN RENAL ALLOGRAFTS1. <i>Transplantation</i> , 1995, 60, 1395-1401.	0.5	69
57	Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: A review of efficacy and mechanisms. <i>American Journal of Kidney Diseases</i> , 1995, 26, 701-715.	2.1	68
58	The Association of Cytomegalovirus Sero-Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis. <i>American Journal of Transplantation</i> , 2003, 3, 445-451.	2.6	66
59	Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor-recipient combination. <i>American Journal of Transplantation</i> , 2019, 19, 425-433.	2.6	66
60	Incidence, Predictors, and Associated Outcomes of Atrial Fibrillation after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 288-296.	2.2	63
61	Inpatient COVID-19 outcomes in solid organ transplant recipients compared to non-solid organ transplant patients: A retrospective cohort. <i>American Journal of Transplantation</i> , 2021, 21, 2498-2508.	2.6	63
62	Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2018, 71, 315-326.	2.1	62
63	APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. <i>Kidney International Reports</i> , 2020, 5, 278-288.	0.4	62
64	The national landscape of deceased donor kidney transplantation for the highly sensitized: Transplant rates, waitlist mortality, and posttransplant survival under KAS. <i>American Journal of Transplantation</i> , 2019, 19, 1129-1138.	2.6	61
65	The COVID-19 nephrology compendium: AKI, CKD, ESKD and transplantation. <i>BMC Nephrology</i> , 2020, 21, 449.	0.8	61
66	Autoreactive kidney-infiltrating T-cell clones in murine lupus nephritis. <i>Kidney International</i> , 1992, 42, 851-859.	2.6	60
67	The Economic Implications of HLA Matching in Cadaveric Renal Transplantation. <i>New England Journal of Medicine</i> , 1999, 341, 1440-1446.	13.9	60
68	Effect of Extended Coverage of Immunosuppressive Medications by Medicare on the Survival of Cadaveric Renal Transplants. <i>American Journal of Transplantation</i> , 2001, 1, 69-73.	2.6	60
69	A Randomized, Prospective, Pharmacoeconomic Trial of Tacrolimus versus Cyclosporine in Combination with Thymoglobulin in Renal Transplant Recipients. <i>Transplantation</i> , 2005, 80, 41-46.	0.5	60
70	Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. <i>Reviews in Medical Virology</i> , 2013, 23, 97-125.	3.9	60
71	Biological Variation of Donor-Derived Cell-Free DNA in Renal Transplant Recipients: Clinical Implications. <i>Journal of Applied Laboratory Medicine</i> , The, 2017, 2, 309-321.	0.6	59
72	Cytomegalovirus Disease after Prophylaxis with Oral Ganciclovir in Renal Transplantation: The Importance of HLA-DR Matching. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 780-785.	3.0	58

#	ARTICLE	IF	CITATIONS
73	Prospective, Pilot, Open-Label, Short-Term Study of Conversion to Leflunomide Reverses Chronic Renal Allograft Dysfunction. <i>American Journal of Transplantation</i> , 2002, 2, 867-871.	2.6	54
74	Associations of Pre-Transplant Prescription Narcotic Use with Clinical Complications after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2015, 41, 165-176.	1.4	54
75	Clinical and economic consequences of first-year urinary tract infections, sepsis, and pneumonia in contemporary kidney transplantation practice. <i>Transplant International</i> , 2016, 29, 241-252.	0.8	54
76	Thymoglobulin Induction Is Safe and Effective in Live-Donor Renal Transplantation: A Single Center Experience. <i>Transplantation</i> , 2006, 81, 1285-1289.	0.5	53
77	The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocation. <i>American Journal of Kidney Diseases</i> , 1997, 29, 428-434.	2.1	52
78	Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation: Application of Statistical Approaches to Reduce Bias in Observational Comparisons. <i>Transplantation</i> , 2009, 87, 1520-1529.	0.5	51
79	Urinary microbiome of kidney transplant patients reveals dysbiosis with potential for antibiotic resistance. <i>Translational Research</i> , 2017, 181, 59-70.	2.2	51
80	Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 41-52.	0.7	50
81	Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. <i>Transplant International</i> , 2016, 29, 1226-1236.	0.8	50
82	Effects of recurrent urinary tract infections on graft and patient outcomes after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1758-1766.	0.4	50
83	Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study. <i>American Journal of Transplantation</i> , 2020, 20, 2997-3007.	2.6	50
84	Inhibitory Interactions between BK and JC Virus among Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 825-831.	3.0	48
85	Race, Relationship and Renal Diagnoses After Living Kidney Donation. <i>Transplantation</i> , 2015, 99, 1723-1729.	0.5	48
86	Sirolimus-induced leukocytoclastic vasculitis. <i>Transplantation</i> , 2002, 74, 739-740.	0.5	47
87	CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 397-402.	0.4	47
88	Pharmacokinetics of Tacrolimus in Kidney Transplant Recipients: Twice Daily Versus Once Daily Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 621-625.	2.6	47
89	Impact of Prophylactic Versus Preemptive Valganciclovir on Long-Term Renal Allograft Outcomes. <i>Transplantation</i> , 2010, 90, 412-418.	0.5	47
90	Novel immunosuppressive agents in kidney transplantation. <i>World Journal of Transplantation</i> , 2013, 3, 68.	0.6	47

#	ARTICLE	IF	CITATIONS
91	Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. <i>Transplant International</i> , 2018, 31, 198-211.	0.8	46
92	Cardiac Evaluation before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1115-1124.	2.2	44
93	Initial skin cancer screening for solid organ transplant recipients in the United States: Delphi method development of expert consensus guidelines. <i>Transplant International</i> , 2019, 32, 1268-1276.	0.8	44
94	A diverse virome in kidney transplant patients contains multiple viral subtypes with distinct polymorphisms. <i>Scientific Reports</i> , 2016, 6, 33327.	1.6	44
95	Transplant Center Volume and the Risk of Pancreas Allograft Failure. <i>Transplantation</i> , 2017, 101, 2757-2764.	0.5	43
96	Statin use after renal transplantation: a systematic quality review of trial-based evidence. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2378-2386.	0.4	42
97	The changing landscape of live kidney donation in the United States from 2005 to 2017. <i>American Journal of Transplantation</i> , 2019, 19, 2614-2621.	2.6	42
98	Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. <i>Transplant International</i> , 2004, 17, 609-616.	0.8	42
99	Quantifying Prognostic Impact of Prescription Opioid Use Before Kidney Transplantation Through Linked Registry and Pharmaceutical Claims Data. <i>Transplantation</i> , 2015, 99, 187-196.	0.5	41
100	COVID-19 Clinical Outcomes in Solid Organ Transplant Recipients During the Omicron Surge. <i>Transplantation</i> , 2022, 106, e346-e347.	0.5	41
101	Sensitivity of Billing Claims for Cardiovascular Disease Events among Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1213-1221.	2.2	40
102	Epstein-Barr virus and renal transplantation. <i>Transplantation Reviews</i> , 2017, 31, 55-60.	1.2	39
103	Letermovir for the management of cytomegalovirus infection. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 235-241.	1.9	39
104	Incremental Value of the Pancreas Allograft to the Survival of Simultaneous Pancreas-Kidney Transplant Recipients. <i>Diabetes Care</i> , 2009, 32, 600-602.	4.3	38
105	Consistency of Racial Variation in Medical Outcomes Among Publicly and Privately Insured Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 316-324.	0.5	38
106	Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. <i>Transplantation</i> , 2021, 105, 170-176.	0.5	37
107	Delayed-Onset Cytomegalovirus Disease Coded During Hospital Readmission After Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 187-194.	0.5	36
108	Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. <i>Transplantation</i> , 2019, 103, 2373-2382.	0.5	36

#	ARTICLE	IF	CITATIONS
109	Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients. <i>Transplantation Direct</i> , 2020, 6, e543.	0.8	36
110	Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. <i>Archives of Medical Science</i> , 2011, 2, 278-286.	0.4	34
111	Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature. <i>Transplant International</i> , 2015, 28, 1121-1125.	0.8	34
112	Iron deficiency anemia and iron losses after renal transplantation. <i>Transplant International</i> , 2009, 22, 434-440.	0.8	33
113	The impact of kidney transplantation on heart failure risk varies with candidate body mass index. <i>American Heart Journal</i> , 2009, 158, 972-982.	1.2	33
114	Serum Sickness After Treatment With Rabbit Antithymocyte Globulin in Kidney Transplant Recipients With Previous Rabbit Exposure. <i>American Journal of Kidney Diseases</i> , 2010, 55, 141-143.	2.1	33
115	Incidence, Risk Factors and Outcomes of Delayed-onset Cytomegalovirus Disease in a Large Retrospective Cohort of Lung Transplant Recipients. <i>Transplantation</i> , 2015, 99, 1658-1666.	0.5	33
116	Antithymocyte Globulin Induction in Living Donor Renal Transplant Recipients. <i>Transplantation</i> , 2012, 94, 331-337.	0.5	32
117	Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1314-1325.	3.0	32
118	Telemedicine in the Care of Kidney Transplant Recipients With Coronavirus Disease 2019: Case Reports. <i>Transplantation Proceedings</i> , 2020, 52, 2620-2625.	0.3	32
119	Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 517-523.	2.2	31
120	Induction Therapy in Renal Transplant Recipients. <i>Drugs</i> , 2012, 72, 671-683.	4.9	31
121	Total Penis, Scrotum, and Lower Abdominal Wall Transplantation. <i>New England Journal of Medicine</i> , 2019, 381, 1876-1878.	13.9	31
122	West Nile Virus-Associated Meningoencephalitis in Two Chronically Immunosuppressed Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2003, 3, 1312-1315.	2.6	30
123	Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. <i>Trials</i> , 2015, 16, 365.	0.7	30
124	Symptomatic hyperammonemia after lung transplantation: Lessons learnt. <i>Hemodialysis International</i> , 2014, 18, 185-191.	0.4	29
125	Risk of ESKD in Older Live Kidney Donors with Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1048-1055.	2.2	29
126	Three-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation in type 2 diabetes patients. <i>American Journal of Transplantation</i> , 2020, 20, 788-796.	2.6	28

#	ARTICLE	IF	CITATIONS
127	Prevention and management of cytomegalovirus infection in solid-organ transplantation. Expert Review of Anti-Infective Therapy, 2007, 5, 295-304.	2.0	27
128	Gout after Living Kidney Donation: Correlations with Demographic Traits and Renal Complications. American Journal of Nephrology, 2015, 41, 231-240.	1.4	27
129	Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen. Transplantation, 2003, 76, 1686-1690.	0.5	26
130	Increasing Incidence of New-Onset Diabetes After Transplant Among Pediatric Renal Transplant Patients. Transplantation, 2009, 88, 367-373.	0.5	26
131	Understanding Antihypertensive Medication Use after Living Kidney Donation through Linked National Registry and Pharmacy Claims Data. American Journal of Nephrology, 2014, 40, 174-183.	1.4	26
132	IMPROVED TECHNIQUE FOR TRANSDUODENAL PANCREAS TRANSPLANT BIOPSY. Transplantation, 1994, 57, 752.	0.5	25
133	Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey. Journal of the American Society of Nephrology: JASN, 2006, 17, 2299-2306.	3.0	25
134	Pretransplant Midodrine Use. Transplantation, 2016, 100, 1086-1093.	0.5	25
135	Donor-derived Cell-free DNA and the Prediction of BK Virus-associated Nephropathy. Transplantation Direct, 2020, 6, e622.	0.8	25
136	Rabbit anti-thymocyte globulin for the prevention of acute rejection in kidney transplantation. American Journal of Transplantation, 2019, 19, 2252-2261.	2.6	24
137	Renal Graft Survival and Calcineurin Inhibitor. Transplantation, 2005, 80, 629-633.	0.5	23
138	Tularemia in a Kidney Transplant Recipient: An Unsuspected Case and Literature Review. American Journal of Kidney Diseases, 2005, 45, 926-929.	2.1	23
139	Consequences of Eliminating HLA-B in Deceased Donor Kidney Allocation to Increase Minority Transplantation. American Journal of Transplantation, 2005, 5, 1090-1098.	2.6	23
140	Impaired renal function is associated with worse self-reported outcomes after kidney transplantation. Quality of Life Research, 2011, 20, 1689-1698.	1.5	23
141	Long-Term Trends in Allograft Survival. Advances in Chronic Kidney Disease, 2006, 13, 11-17.	0.6	22
142	Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice. Transplantation, 2017, 101, 858-866.	0.5	21
143	ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation. Transplantation, 2019, 103, 202-209.	0.5	21
144	Infectious Complications in Renal Transplant Recipients. Advances in Chronic Kidney Disease, 2000, 7, 131-146.	2.2	20

#	ARTICLE	IF	CITATIONS
145	Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation. <i>Transplant International</i> , 2017, 30, 153-161.	0.8	20
146	Early Steroid Withdrawal in Deceased-Donor Kidney Transplant Recipients with Delayed Graft Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 175-185.	3.0	20
147	Kidney retransplantation after anti-“programmed cell death-1 (PD-1)“related allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 2264-2268.	2.6	20
148	Cognitive Function, Access to Kidney Transplantation, and Waitlist Mortality Among Kidney Transplant Candidates With or Without Diabetes. <i>American Journal of Kidney Diseases</i> , 2020, 76, 72-81.	2.1	20
149	INCREASED EXPRESSION OF THE HDJ-2 HEAT SHOCK PROTEIN IN BIOPSIES OF HUMAN REJECTED KIDNEY1. <i>Transplantation</i> , 1996, 61, 963-967.	0.5	20
150	Common variable immunodeficiency in a renal transplant patient with severe recurrent bacterial infection: A case report and review of the literature. <i>American Journal of Kidney Diseases</i> , 1995, 25, 947-951.	2.1	18
151	The Economic Impact of Preservation Time in Cadaveric Liver Transplantation. <i>American Journal of Transplantation</i> , 2001, 1, 360-365.	2.6	18
152	Graft-Versus-Host Disease After Simultaneous Pancreas-Kidney Transplantation: A Case Report and Review of the Literature. <i>American Journal of Transplantation</i> , 2014, 14, 2651-2656.	2.6	18
153	The landscape of international living kidney donation in the United States. <i>American Journal of Transplantation</i> , 2019, 19, 2009-2019.	2.6	18
154	Rabbit Antithymocyte Globulin Is More Beneficial in Standard Kidney Than In Extended Donor Recipients. <i>Transplantation</i> , 2009, 87, 1372-1376.	0.5	17
155	Selected Mildly Obese Donors Can Be Used Safely in Simultaneous Pancreas and Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1159-1166.	0.5	16
156	Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts. <i>Kidney360</i> , 2021, 2, 729-736.	0.9	16
157	Chronic Active Antibody-Mediated Rejection Following COVID-19 Infection in a Kidney Transplant Recipient: A Case Report. <i>Transplantation Proceedings</i> , 2021, 53, 1202-1206.	0.3	16
158	TRANSPLANTATION OF VASCULARIZED ALLOGENEIC SKELETAL MUSCLE FOR SCALP RECONSTRUCTION IN A RENAL TRANSPLANT PATIENT. <i>Transplantation</i> , 1998, 65, 1605-1610.	0.5	16
159	Cytomegalovirus and HLA-A, B, and DR locus interactions: Impact on renal transplant graft survival. <i>American Journal of Kidney Diseases</i> , 1997, 30, 766-771.	2.1	15
160	Donor Derived Cell Free DNA in Kidney Transplantation: The Circa 2020“2021 Update. <i>Transplant International</i> , 0, 35, .	0.8	15
161	Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1197-1200.	0.4	14
162	Cyclosporine Minimization and Cost Reduction in Renal Transplant Recipients Receiving a C2-Monitored, Cyclosporine-Based Quadruple Immunosuppressive Regimen. <i>Transplantation</i> , 2004, 78, 1198-1203.	0.5	14

#	ARTICLE	IF	CITATIONS
163	Expanding the Evidence Base in Transplantation: The Complementary Roles of Randomized Controlled Trials and Outcomes Research. <i>Transplantation</i> , 2008, 86, 18-25.	0.5	14
164	Cardioprotective Medication Use After Acute Myocardial Infarction in Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 91, 1120-1126.	0.5	14
165	Isohemagglutinin titering performed on an automated solid-phase and hemagglutinin-based analyzer is comparable to results obtained by manual gel testing. <i>Transfusion</i> , 2020, 60, 628-636.	0.8	14
166	Development and Validation of an Inflammatory-Frailty Index for Kidney Transplantation. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 470-477.	1.7	14
167	Therapies for Chronic Allograft Rejection. <i>Frontiers in Pharmacology</i> , 2021, 12, 651222.	1.6	14
168	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	0.8	14
169	Cultured mesangial cells from autoimmune MRL-lpr mice have decreased secreted and surface M-CSF. <i>Kidney International</i> , 1992, 42, 279-284.	2.6	13
170	EBV-associated recurrent Hodgkin's disease after renal transplantation. <i>Transplant International</i> , 2006, 19, 338-341.	0.8	13
171	Pulmonary Phaeohyphomycosis Caused by <i>Phaeoacremonium</i> in a Kidney Transplant Recipient: Successful Treatment with Posaconazole. <i>Case Reports in Medicine</i> , 2014, 2014, 1-5.	0.3	13
172	Single-Dose Rituximab for Recurrent Glomerulonephritis Post-Renal Transplant. <i>American Journal of Nephrology</i> , 2015, 41, 37-47.	1.4	13
173	A Pharmacoeconomic Comparison of Antithymocyte Globulin and Muromonab CD3 Induction Therapy in Renal Transplant Recipients. <i>Pharmacoeconomics</i> , 1997, 11, 237-245.	1.7	12
174	Functional Antibodies to Leukocyte Adhesion Molecules in Antithymocyte Globulins. <i>Transplantation</i> , 2003, 75, 577-578.	0.5	12
175	Antidepressant medication use before and after kidney transplant: implications for outcomes - a retrospective study. <i>Transplant International</i> , 2018, 31, 20-31.	0.8	12
176	Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. <i>Transplantation Direct</i> , 2018, 4, e389.	0.8	12
177	Physical Impairment and Access to Kidney Transplantation. <i>Transplantation</i> , 2020, 104, 367-373.	0.5	12
178	Clinical Validation of an Immune Quiescence Gene Expression Signature in Kidney Transplantation. <i>Kidney360</i> , 2021, 2, 1998-2009.	0.9	12
179	Novel Methods for Tracking Long-Term Maintenance Immunosuppression Regimens. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 117-124.	2.2	11
180	Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study. <i>Nature Clinical Practice Nephrology</i> , 2007, 3, 602-603.	2.0	10

#	ARTICLE	IF	CITATIONS
181	The Tradeoff Between the Risks of Acute Rejection and New-Onset Diabetes After Kidney Transplant. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1026-1028.	2.1	10
182	Understanding Medical Care of Transplant Recipients through Integrated Registry and Pharmacy Claims Data. <i>American Journal of Nephrology</i> , 2013, 38, 420-429.	1.4	10
183	Tacrolimus-Induced Cardiomyopathy in an Adult Renal Transplant Recipient. <i>Pharmacotherapy</i> , 2015, 35, 1109-1116.	1.2	10
184	Gender differences in use of prescription narcotic medications among living kidney donors. <i>Clinical Transplantation</i> , 2015, 29, 927-937.	0.8	10
185	The Long-Term Outcomes and Costs of Diabetes Mellitus among Renal Transplant Recipients: Tacrolimus versus Cyclosporine. <i>Value in Health</i> , 2011, 14, 443-449.	0.1	9
186	JC polyoma virus and kidney disease. <i>Kidney International</i> , 2014, 85, 1242.	2.6	9
187	A Case Report of Adrenocorticotrophic Hormone to Treat Recurrent Focal Segmental Glomerular Sclerosis Post-Transplantation and Biomarker Monitoring. <i>Frontiers in Medicine</i> , 2015, 2, 13.	1.2	9
188	Infectious complications in kidney transplant recipients: review of the literature. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2005, 16, 453-97.	0.4	9
189	LIVING UNRELATED RENAL TRANSPLANTATION FOR SICKLE CELL NEPHROPATHY. <i>Transplantation</i> , 1995, 59, 794-795.	0.5	8
190	A 3-Year Follow-Up of Pre-Emptive vs Deferred Treatment of Cytomegalovirus Disease in Renal Transplantation. <i>Clinical Drug Investigation</i> , 2000, 19, 367-374.	1.1	8
191	Diabetes Mellitus in Living Pancreas Donors. <i>Transplantation</i> , 2017, 101, 1276-1281.	0.5	8
192	Functional independence, access to kidney transplantation and waitlist mortality. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 870-877.	0.4	8
193	General Approach to the Clinical Care of Solid Organ Transplant Recipients with COVID-19 Infection. <i>Current Transplantation Reports</i> , 2020, 7, 366-378.	0.9	8
194	Utility of Serial Donor-derived Cell-free DNA Measurements for Detecting Allograft Rejection in a Kidney Transplant Recipient After PD-1 Checkpoint Inhibitor Administration. <i>Transplantation Direct</i> , 2021, 7, e656.	0.8	8
195	Treatment of BK Viremia after Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 445-447.	2.2	7
196	Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. <i>Clinical Transplantation</i> , 2016, 30, 435-444.	0.8	7
197	Quantitative Evaluation of the Impact of Ethylenediaminetetraacetic Acid Pretreatment on Single-Antigen Bead Assay. <i>Transplantation Direct</i> , 2017, 3, e194.	0.8	7
198	Influence of pretransplant midodrine use on outcomes after kidney transplantation. <i>Clinical Transplantation</i> , 2018, 32, e13366.	0.8	7

#	ARTICLE	IF	CITATIONS
199	WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure. American Journal of Transplantation, 2019, 19, 2833-2845.	2.6	7
200	Cognitive impairment burden in older and younger adults across the kidney transplant care continuum. Clinical Transplantation, 2021, 35, e14425.	0.8	7
201	Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.. Journal of Clinical Oncology, 2022, 40, 9507-9507.	0.8	7
202	Renal Allograft Infiltrating Lymphocytes: Frequency of Tissue Specific Lymphocytes. Human Immunology, 1997, 55, 140-147.	1.2	6
203	Safety of Neoral conversion in maintenance renal transplant patients: A one-year, double-blind study. Kidney International, 1999, 56, 685-691.	2.6	6
204	Associations of Recipient Illness History With Hypertension and Diabetes After Living Kidney Donation. Transplantation, 2011, 91, 1227-1232.	0.5	6
205	Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. Therapeutic Drug Monitoring, 2020, 42, 679-685.	1.0	6
206	Securing the future of kidney transplantation by addressing the challenges of transplant nephrology. American Journal of Transplantation, 2021, 21, 37-43.	2.6	6
207	Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation. BMC Nephrology, 2021, 22, 26.	0.8	6
208	Changes in Functional Status Among Kidney Transplant Recipients: Data From the Scientific Registry of Transplant Recipients. Transplantation, 2021, 105, 2104-2111.	0.5	6
209	IN VITRO T CELL PROLIFERATION FROM KIDNEY ALLOGRAFT BIOPSIES WITH UNREMARKABLE PATHOLOGY. Transplantation, 2002, 73, 142-145.	0.5	6
210	Partial lipodystrophy magnetic resonance findings in one case. The Journal of Computed Tomography, 1988, 12, 287-291.	0.1	5
211	<i>Mille Verba</i>: Seeking Safe and Efficacious Anemia Management. Seminars in Dialysis, 2009, 22, 590-591.	0.7	5
212	Introduction: Kidney Transplantation and Viral Infection. Seminars in Nephrology, 2016, 36, 343.	0.6	5
213	Kidney Dyads: Caregiver Burden and Relationship Strain Among Partners of Dialysis and Transplant Patients. Transplantation Direct, 2020, 6, e566.	0.8	5
214	Donor-derived Cell-free DNA Kinetics Post-kidney Transplant Biopsy. Transplantation Direct, 2021, 7, e703.	0.8	5
215	Association between ddâ€fDNA levels, de novo donor specific antibodies, and eGFR decline: An analysis of the DART cohort. Clinical Transplantation, 2021, 35, e14402.	0.8	5
216	Longâ€f term kidney function and survival in recipients of allografts from living kidney donors with hypertension: a national cohort study. Transplant International, 2021, 34, 1530-1541.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Hepatitis E virus infection and rejection in kidney transplant recipients. <i>Transplant Immunology</i> , 2022, 70, 101517.	0.6	5
218	Leflunomide: is there a place for its use in transplantation?. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 317-322.	0.8	4
219	Complete Genome Sequence of BK Polyomavirus Subtype Ib-1 Detected in a Kidney Transplant Patient with BK Viremia Using Shotgun Sequencing. <i>Genome Announcements</i> , 2017, 5, .	0.8	4
220	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. <i>Clinical Transplantation</i> , 2020, 34, e14118.	0.8	4
221	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2021, 105, 2632-2638.	0.5	4
222	Deceased-Donor Acute Kidney Injury and BK Polyomavirus in Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 765-775.	2.2	4
223	The Impact of COVID-19 on the State of Clinical and Laboratory Research Globally in Transplantation in May 2020. <i>Transplantation</i> , 2020, 104, 2252-2257.	0.5	4
224	COVID-19 Early After a Deceased Donor Kidney Transplant Surgery. <i>Transplantation</i> , 2020, 104, e354-e355.	0.5	4
225	Three-year post-transplant Medicare payments in kidney transplant recipients: associations with pre-transplant comorbidities. <i>Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia</i> , 2011, 22, 24-39.	0.4	4
226	Treatment of HUS/TTP. <i>American Journal of Kidney Diseases</i> , 1992, 19, 391-393.	2.1	3
227	Utility of a Mathematical Nomogram to Predict Delayed Graft Function: A Single-Center Experience???Critique. <i>Transplantation</i> , 2007, 83, 524-525.	0.5	3
228	Cytomegalovirus and Anemia: Not Just for Transplant Anymore. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 1613-1615.	3.0	3
229	Immunosuppressive Agents. , 2016, , 31-46.		3
230	Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor. <i>Transplantation</i> , 2017, 101, e287-e288.	0.5	3
231	The Privilege of Induction Avoidance and Calcineurin Inhibitors Withdrawal in 2 Haplotype HLA Matched White Kidney Transplantation. <i>Transplantation Direct</i> , 2017, 3, e133.	0.8	3
232	Long-term renal function in living kidney donors with simple renal cysts: A retrospective cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13905.	0.8	3
233	Donor-Derived Cell-Free DNA in Kidney Transplantation: Origins, Present and a Look to the Future. <i>Medicina (Lithuania)</i> , 2021, 57, 482.	0.8	3
234	Utility of Donor-Derived Cell-Free DNA in Detecting ABMR in Patients With AT1R Antibodies. <i>Kidney International Reports</i> , 2021, 6, 2706-2708.	0.4	3

#	ARTICLE	IF	CITATIONS
235	THE ECONOMIC BENEFIT OF ALLOCATION OF KIDNEYS BASED ON CROSS-REACTIVE GROUP MATCHING ¹² . Transplantation, 2000, 70, 537-540.	0.5	3
236	De Novo Membranoproliferative Glomerulonephritis III in a renal transplant patient: Case report and review of the literature. Transplant International, 2012, 25, e58-e61.	0.8	2
237	Cytomegalovirus. Transplantation, 2018, 102, 898-899.	0.5	2
238	Transformation in Immunosuppression: Are We Ready for it?. Journal of the American Society of Nephrology: JASN, 2018, 29, 1791-1792.	3.0	2
239	Talimogene Laherparepvec Use in Kidney Transplant Recipient. Transplantation, 2020, 104, e109-e110.	0.5	2
240	Apical Sparing Pattern of Longitudinal Strain and Positive Bone Scintigraphy in Metastatic Myocardial Calcification. JACC: Case Reports, 2020, 2, 809-813.	0.3	2
241	Economic impacts of alternative kidney transplant immunosuppression: A national cohort study. Clinical Transplantation, 2020, 34, e13813.	0.8	2
242	Abundance of Multidrug Resistance Efflux Pumps in the Urinary Metagenome of Kidney Transplant Patients. BioMed Research International, 2020, 2020, 1-9.	0.9	2
243	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. Clinical Transplantation, 2022, 36, e14660.	0.8	2
244	Is there a correlation between atherosclerosis and renal resistive indices in kidney transplant recipients?. Nature Clinical Practice Nephrology, 2006, 2, 64-65.	2.0	1
245	American Society of Nephrology Quiz and Questionnaire 2012: Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1267-1272.	2.2	1
246	The role of rabbit antithymocyte globulin in renal transplantation. Expert Opinion on Orphan Drugs, 2014, 2, 971-987.	0.5	1
247	Singing a New SONG. Transplantation, 2017, 101, 1748-1750.	0.5	1
248	Moving from transplant as a treatment to transplant as a cure. Journal of Clinical Investigation, 2020, 130, 2189-2191.	3.9	1
249	A New Product Pricing Model Using Intracorporate Market Perceptions to Extract the Value of Additional Information. Pharmacoeconomics, 1998, 14, 71-77.	1.7	0
250	ECONOMIC OUTCOMES OF SIMULTANEOUS KIDNEY-PANCREAS TRANSPLANTATION (SKP) COMPARED TO KIDNEY ALONE (KA).. Transplantation, 2000, 69, S270.	0.5	0
251	ECONOMIC IMPACT OF COLD ISCHEMIA IN LIVER TRANSPLANT.. Transplantation, 2000, 69, S367.	0.5	0
252	Current Concepts of Immunosuppression and Side Effects. , 2009, , 11-30.		0

#	ARTICLE	IF	CITATIONS
253	Randomized Trial of Pre-Emptive or Prophylactic Valganciclovir Therapy for Prevention of Cytomegalovirus Infection in Renal Transplantation. <i>Journal of the American Society of Nephrology</i> ; JASN, 2012, 23, 1446-1448.	3.0	0
254	Starting Well: Induction Immunosuppression after Organ Transplantation. <i>Transplant International</i> , 2013, 26, 661-661.	0.8	0
255	The relevance of the FAVORIT blood pressure associations. <i>Nature Reviews Nephrology</i> , 2014, 10, 366-367.	4.1	0
256	Extended-release tacrolimus tablets for preventing organ transplant rejection. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 1079-1086.	0.5	0
257	Biologics in Transplantation (Anti-thymocyte Globulin, Belatacept, Alemtuzumab): How Should We Use Them?. <i>Current Transplantation Reports</i> , 2017, 4, 82-90.	0.9	0
258	A Snapshot of Antibody-Mediated Rejection Goes Viral. <i>Transplantation</i> , 2017, 101, 227.	0.5	0
259	Everyday People Sing a Simple Song: Establishing a Core Outcome for Life Participation. <i>Transplantation</i> , 2019, 103, 1078-1079.	0.5	0
260	Financial incentives versus standard of care to improve patient compliance with live kidney donor follow-up: protocol for a multi-center, parallel-group randomized controlled trial. <i>BMC Nephrology</i> , 2020, 21, 465.	0.8	0
261	Combining Clinical and Genetic Factors to Predict Tacrolimus Levels in Pediatric Solid Organ Transplants. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	0
262	The Science Is Only as Good as the Data: The Case of Fontan-associated Liver Disease. <i>Transplantation</i> , 2021, 105, 23-24.	0.5	0